Case report
remains well 17 months following testicular relapse and notable for initial remission durations of at least 2 years and post-relapse treatment with systemic chemotherapy.
2,5 more than 15 months off all anti-leukemic therapy. While there have been no prior reports of isolated testicular relapse after allogeneic BMT for AML, it is known that durable second remissions have been achieved in some Discussion patients with marrow relapse when it occurred more than 1 year following transplant. In addition, patients have been Studies of relapse in ALL have previously identified the testis as a 'privileged site', where leukemic blasts are parreported with isolated testicular relapse after BMT for ALL and subsequent long-term disease-free survival.
17
tially protected from the cytotoxic effects of chemotherapy and isolated recurrence is well described. 1 Perhaps because This report describes an isolated testicular relapse 5 years after allogeneic BMT for AML in first remission and points of the high-dose systemic therapy used in the treatment of AML, isolated extramedullary relapse in general is relaout the necessity for careful testicular examination during post-transplant follow-up. For patients with monocytic varitively uncommon 7,9 and isolated testicular recurrence is very rare. While not noted in several large series of relapsed ants of AML, who are at increased risk for extramedullary involvement at diagnosis, at relapse, and perhaps after patients, 8,9 a number of individual cases have been described in adult and pediatric populations.
2-6 Leukemic BMT as well, the potential role of TBI-containing conditioning regimens for eradication of leukemia from extrainfiltration of the testicle may be more common than is appreciated clinically in patients with marrow relapse howmedullary sites requires further investigation. In patients such as the one reported here, where an isolated extramedever, as post-mortem examination has demonstrated gonadal involvement in 30-70% of males succumbing to proullary relapse occurred late after BMT, aggressive attempts at reinduction are warranted. While there is not sufficient gressive leukemia.
10,11
The only recognized risk factor for extramedullary length of follow-up to ascertain if this patient is cured, sustained remission has been achieved. involvement in AML at diagnosis or relapse is the presence of the monocytic variants -M4 or M5. [12] [13] [14] Within these subtypes CNS disease predominates, followed by skin and gums, but the testicle is more often involved than with other
